Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

In fact, C. diff infections often spring up because the bacteria take advantage of a weakened microbiome following treatment with antibiotics for other diseases. “Treatment of C. difficile ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

When those bacteria die — for instance, as a result of antibiotic treatment for an unrelated infection — the large intestine ...

There are about 500,000 cases of C. difficile each year; about one in six people with the infection will see it come back within two to eight weeks of the initial infection. “Treatment of C.

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

Have a weakened immune system due to cancer, organ transplant, or treatment with immunosuppressive drugs (such as people with inflammatory bowel disease or autoimmune conditions). Have close contact ...

In the period spanning 2017-2021, a mere 12 new antibiotics entered the market, with only one capable of targeting all the ...

Clostridium difficile infection (CDI ... Although metronidazole and vancomycin are and have been the mainstay treatment options for CDI, there are some unmet medical and therapeutical needs.

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

Once C-diff is in the ascendancy it can be very hard to shift – the traditional treatment is antibiotics but a significant number of patients do not respond and are left with relentless and ...